PT - JOURNAL ARTICLE AU - Esmaeili, Shadisadat AU - Owens, Katherine AU - Wagoner, Jessica AU - Polyak, Stephen J. AU - White, Judith M. AU - Schiffer, Joshua T. TI - A unifying model to explain high nirmatrelvir therapeutic efficacy, low post-exposure prophylaxis efficacy, and frequent viral rebound AID - 10.1101/2023.08.23.23294505 DP - 2024 Jan 01 TA - medRxiv PG - 2023.08.23.23294505 4099 - http://medrxiv.org/content/early/2024/01/30/2023.08.23.23294505.short 4100 - http://medrxiv.org/content/early/2024/01/30/2023.08.23.23294505.full AB - In a pivotal trial, a 5-day course of oral ritonavir-boosted nirmatrelvir, given early during symptomatic infection, decreased hospitalization and death by 89.1% and reduced nasal viral load by 0.87 log relative to placebo in high-risk individuals. Yet, ritonavir-boosted nirmatrelvir failed as post-exposure prophylaxis in a follow-up trial, and frequent viral rebound has been observed in the community. We developed a mathematical model capturing viral-immune dynamics and nirmatrelvir pharmacokinetics that recapitulated viral loads from this and another clinical trial. Our results suggest that nirmatrelvir’s in vivo potency is significantly lower than in vitro assays predict. A maximally potent agent would reduce the viral load by approximately 3.5 logs relative to placebo at 5 days. The model identifies that earlier initiation and shorter treatment duration are key predictors of post-treatment rebound. Extension of early symptomatic treatment to 10 days and post-exposure prophylaxis to 15 days, rather than increasing dose or dosing frequency, is predicted to significantly lower the incidence of viral rebound.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by National Institutes of Health (NIH) grants R01AI169427, R01AI121129, and R01AI177512Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data analyzed in this work was previously published by Hay et al. and Schilling et al. and is available on github at https://github.com/gradlab/SC2-kinetics-immune-history and https://github.com/jwatowatson/PLATCOV-Molnupiravir/tree/V1.0I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll code, and materials used in the analysis is available on github at https://github.com/sEsmaeili/Covid_Rebound The data analyzed in this work was previously published by Hay et al. and Schilling et al. and is available on github at https://github.com/gradlab/SC2-kinetics-immune-history and https://github.com/jwatowatson/PLATCOV-Molnupiravir/tree/V1.0 https://github.com/gradlab/SC2-kinetics-immune-history https://github.com/jwatowatson/PLATCOV-Molnupiravir/tree/V1.0